Abstract:Although epidermal growth factor receptor (EGFR) inhibitors have been used to treat non-small cell lung cancer (NSCLC) for decades with great success in patients with EGFR mutations, acquired-resistance inevitably occurs after long-term exposure to the treatment of EGFR inhibitors. Glycolysis is a predominant process for most cancer cells to utilize glucose, which referred to as the Warburg Effect. Targeting critical enzymes, such as pyruvate dehydrogenase kinase 1 (PDK1) that inversely regulating the process of glycolysis could be a promising approach to work alone or in combination with other treatments for cancer therapy. The purpose of this study is to evaluate whether PDK1 inhibition could enhance the anti-cancer effects of EGFR-TKi. Herein, we utilized a recently reported PDK1 inhibitor 2,2-Dichloro-1-(4-isopropoxy-3-nitrophenyl)ethan-1-one (Cpd64), which was more potent and selective than dichloroacetate (DCA) and/or dichloroacetophenone (DAP), to study the mechanism of PDK1 inhibition in TKi-mediated anti-cancer activity. We found that the introduction of Cpd64 in EGFR-TKi therapy enhanced the anti-proliferative effects in EGFR-mutant NSCLC cells under hypoxia. In particular, Cpd64 was shown to increase the activity of pyruvate dehydrogenase (PDH) and improved XPHOS, such as elevated mitochondrial respiration, and increased ATP generation, which effectively modulated the upregulation of PDK1 by EGFR-TKi treatment. We have observed that Cpd64 effectively enhanced the tumor growth inhibition induced by erlotinib in a NCI-H1975 xenograft mouse model. Collectively, our results suggested that combined use of selective PDK inhibitor and EGFR-TKi could be a potential strategy for NSCLC therapy.

Unexpected Discovery of Dichloroacetate Derived Adenosine Triphosphate Competitors Targeting Pyruvate Dehydrogenase Kinase to Inhibit Cancer Proliferation.

Anticancer effects of some novel dichloroacetophenones through the inhibition of pyruvate dehydrogenase kinase 1

Reprogramming Energy Metabolism with Synthesized PDK Inhibitors Based on Dichloroacetate Derivatives and Targeted Delivery Systems for Enhanced Cancer Therapy

Targeting the Pyruvate Dehydrogenase Complex/pyruvate Dehydrogenase Kinase (PDC/PDK) Axis to Discover Potent PDK Inhibitors Through Structure-Based Virtual Screening and Pharmacological Evaluation.

Development of Dichloroacetamide Pyrimidines As Pyruvate Dehydrogenase Kinase Inhibitors to Reduce Cancer Cell Growth: Synthesis and Biological Evaluation

Dichloroacetophenones targeting at pyruvate dehydrogenase kinase 1 with improved selectivity and antiproliferative activity: Synthesis and structure-activity relationships.

Novel Dichloroacetophenone-Based PDHK1 Inhibitors as Potent Anticancer Agents

Synthesis and Biological Evaluation of (R)-3,3,3-trifluoro-2-hydroxy-2-methylpropionamides As Pyruvate Dehydrogenase Kinase 1 (PDK1) Inhibitors to Reduce the Growth of Cancer Cells

Recent advances in pyruvate dehydrogenase kinase inhibitors: Structures, inhibitory mechanisms and biological activities

Synthesis, biological evaluation and structure-activity relationship of novel dichloroacetophenones targeting pyruvate dehydrogenase kinases with potent anticancer activity

Targeting Tumor Metabolism for Cancer Treatment: is Pyruvate Dehydrogenase Kinases (pdks) a Viable Anticancer Target?

Rational Design of Mitochondria-Targeted Pyruvate Dehydrogenase Kinase 1 Inhibitors with Improved Selectivity and Antiproliferative Activity.

High-throughput Screening of Novel Pyruvate Dehydrogenase Kinases Inhibitors and Biological Evaluation of Their in Vitro and in Vivo Antiproliferative Activity.

Development of the First Generation of Disulfide-Based Subtype-Selective and Potent Covalent Pyruvate Dehydrogenase Kinase 1 (PDK1) Inhibitors

Targeting PDK1 with dichloroacetophenone to inhibit acute myeloid leukemia (AML) cell growth

Development of dual inhibitors targeting pyruvate dehydrogenase kinases and human lactate dehydrogenase A: High-throughput virtual screening, synthesis and biological validation

Development of pyruvate dehydrogenase kinase inhibitors in medicinal chemistry with particular emphasis as anticancer agents.

Inhibition of Pyruvate Dehydrogenase Kinase 1 Enhances the Anti-Cancer Effect of EGFR Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer.

Computational Study on New Natural Compound Inhibitors of Pyruvate Dehydrogenase Kinases

Biochemical Discovery, Intracellular Evaluation, and Crystallographic Characterization of Synthetic and Natural Product Adenosine 3',5'-Cyclic Monophosphate-Dependent Protein Kinase A (PKA) Inhibitors.

Targeting ATP catalytic activity of chromodomain helicase CHD1L for the anticancer inhibitor discovery